More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
Some heart teams may only target the culprit lesions when treating older patients, but new research confirms this increases the risk of several unfavorable outcomes.
Datapoints contained in structured radiology reports can be readily mined to guide decisions around long-term clinical, business and population-health aims.
Steen Dalby Kristensen, a cardiologist with Aarhus University Hospital in Denmark, detailed some of the hottest topics at the European Society of Cardiology's annual meeting.
Here’s a profile of the quintessential social media influencer working in radiology: male, physician, subspecialized, academic and/or administrative leader ...
The ILUMIEN IV and OCTOBER trials helped illustrate that the benefits of intravascular ultrasound also are seen with optical coherence tomography. Both trials were included in the new meta-analysis presented at ESC Congress 2023.
